secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2026-08-12T20:14:11+00:00
Accession:  0001213900-26-088365
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron Q2 net loss widens to $6.1M; cash $10.1M into Q4 2026; ELPIS II top-line Sept
--------------------------------------------------------------------------------

- Revenue flat at $0.3M; gross profit up 25% to ~$0.2M; G&A up 23% to $3.2M; R&D up 7% to $3.2M.
- Net loss $6.1M vs $5.0M YoY; cash $10.1M expected to fund into Q4 2026; seeks additional financing.
- ELPIS II Phase 2b top-line results for laromestrocel in HLHS expected September 2026; DMC no safety concerns.
- Selected as XPRIZE Healthspan Finalist; receives $1.0M Milestone 2 Award; eligible for up to $81M Grand Prize.
- Three new independent directors added to board; EMA SME status granted in June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/0001213900-26-088365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/ea0301757-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-088365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer